Back to News
Market Impact: 0.15
Kaplan Fox Encourages Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Contact the Firm Before the Deadline on September 28, 2026 for a Leadership Role
Source: globenewswire.com
Legal & LitigationCompany Fundamentals
A class action lawsuit has been filed against Capricor Therapeutics (NASDAQ: CAPR) on behalf of investors. With no disclosed financial damages or specific allegations in the provided text, the impact is likely limited in the near term, but it adds legal overhang risk for the stock.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.20
Ticker Sentiment
CAPR-0.80
More News
- Nvidia GPUs are everywhere. Here are the ways companies are accessing them
- Bank of America is bullish on these top stocks ahead of earnings
- As companies pour billions into Earth-based AI infrastructure, Google is taking the data center race off-planet
- AI's Supercharging a Scam Economy Bigger Than the Cocaine Trade
- How U.S. know-how is fracking Australia into a gas boom, from Texas oilmen to Trump’s energy secretary
- The world needs Ukraine’s grain. Its farmers are running out of reasons to plant